Director, Corporate Counsel at Axsome Therapeutics Inc

Brisbane, California, United States

Axsome Therapeutics Inc Logo
Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, PharmaceuticalsIndustries

Requirements

  • Juris Doctorate from an accredited law school
  • At least 6+ years of relevant experience as an attorney in a law firm and/or in-house legal department in the life sciences industry (biotechnology, pharmaceuticals, medical device, healthcare or related fields)
  • Contract drafting and negotiation experience, especially in Clinical Trial Agreements (CTA)
  • Self-motivated, detail-oriented and able to consistently provide high quality and timely work product and manage multiple projects
  • Excellent communication and interpersonal skills and stakeholder management
  • Demonstrated ability and track record to act as a team player and build trusted cross-functional and external relationships
  • Strong commitment to compliance and ethics
  • Superior intellect and judgment, with the ability to think critically

Responsibilities

  • Lead the negotiating and drafting of a variety of business contracts, including vendor agreements, IT/software licensing, data privacy agreements, service agreements, clinical trial agreements, confidentiality agreements, consulting agreements, material transfer agreements
  • Provide quality, timely and practical legal advice and guidance, identify, and help resolve legal and business issues arising from regulatory, research and development, IT and clinical activities
  • Foster and develop relationships with internal company stakeholders in legal, clinical operations, clinical development, research and development, IT, outsourcing and quality
  • Support the review and negotiation of IT-related agreements, including SaaS contracts, data processing agreements, cybersecurity policies
  • Identify legal risks related to business operations and develop strategies to mitigate exposure while supporting business objectives
  • Create, support and update library of template contracts, policies, and playbooks
  • Develop training materials on contracting topics for Vera employees and conduct associated company trainings
  • Contribute to legal due diligence activities arising from contract reviews
  • Work cross-functionally with Clinical, Compliance, HR, IT, Finance, and Operations teams to align legal strategies with business goals

Skills

contract negotiation
contract drafting
vendor agreements
IT/software licensing
data privacy agreements
service agreements
clinical operations contracts
R&D agreements
outsourcing agreements

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Performance Bonus
Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.
Potential delays in AXS-07 launch amid growing market anticipation.
Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.
AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI